|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0013216,
umls-concept:C0024299,
umls-concept:C0028429,
umls-concept:C0038952,
umls-concept:C0079772,
umls-concept:C0205420,
umls-concept:C0282460,
umls-concept:C0332174,
umls-concept:C0332283,
umls-concept:C0851346,
umls-concept:C1272745,
umls-concept:C1306673,
umls-concept:C1513822,
umls-concept:C1517067,
umls-concept:C1518321,
umls-concept:C1880171,
umls-concept:C2603343
|
|
pubmed:issue |
35
|
|
pubmed:dateCreated |
2009-12-9
|
|
pubmed:abstractText |
On the basis of the benefits of frontline radiation in early-stage, extranodal, natural killer (NK)/T-cell lymphoma (ENKTL), we conducted a phase II trial of concurrent chemoradiotherapy (CCRT) followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone (VIPD).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AhnYong ChanYC,
pubmed-author:ChoJaehoJ,
pubmed-author:EomHyeon SeokHS,
pubmed-author:HuhJooryungJ,
pubmed-author:KangKi MunKM,
pubmed-author:KimByung SooBS,
pubmed-author:KimChul YongCY,
pubmed-author:KimJin SeokJS,
pubmed-author:KimKihyunK,
pubmed-author:KimSeok JinSJ,
pubmed-author:KimWon SeogWS,
pubmed-author:KoYoung HyehYH,
pubmed-author:LeeGyeong-WonGW,
pubmed-author:LeeSang-WookSW,
pubmed-author:PyoHong RyullHR,
pubmed-author:SuhCheolwonC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6027-32
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19884539-Adult,
pubmed-meshheading:19884539-Aged,
pubmed-meshheading:19884539-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19884539-Chemotherapy, Adjuvant,
pubmed-meshheading:19884539-Cisplatin,
pubmed-meshheading:19884539-Dexamethasone,
pubmed-meshheading:19884539-Disease-Free Survival,
pubmed-meshheading:19884539-Etoposide,
pubmed-meshheading:19884539-Female,
pubmed-meshheading:19884539-Humans,
pubmed-meshheading:19884539-Ifosfamide,
pubmed-meshheading:19884539-Kaplan-Meier Estimate,
pubmed-meshheading:19884539-Lymphoma, Extranodal NK-T-Cell,
pubmed-meshheading:19884539-Male,
pubmed-meshheading:19884539-Middle Aged,
pubmed-meshheading:19884539-Neoplasm Recurrence, Local,
pubmed-meshheading:19884539-Neoplasm Staging,
pubmed-meshheading:19884539-Nose Neoplasms,
pubmed-meshheading:19884539-Prospective Studies,
pubmed-meshheading:19884539-Radiotherapy, Adjuvant,
pubmed-meshheading:19884539-Republic of Korea,
pubmed-meshheading:19884539-Risk Assessment,
pubmed-meshheading:19884539-Time Factors,
pubmed-meshheading:19884539-Treatment Outcome,
pubmed-meshheading:19884539-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
|
|
pubmed:affiliation |
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
